Benzinga | Mar 12, 2021 07:01AM EST

Aravive To Present Phase 1b Data Evaluating AVB-500 In Platinum Resistant Ovarian Cancer At 2021 Society Of Gynecologic Oncology Annual Meeting Mar. 19-25

HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer (PROC) will be presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women's Cancer. Additionally, a trial in progress poster will be presented on an open label Phase 1/2 investigator-sponsored trial of AVB-500 in combination with durvalumab in patients with platinum resistant, recurrent epithelial ovarian cancer. The meeting is being held virtually on March 19-25, 2021.